Brii Biosciences

2137 · HKEX

Public Market Listing

2137HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Brii Biosciences are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
HBsAgMonoclonal antibody
Hepatitis Delta
Chronic Hepatitis Delta

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Tobevibart (VIR-3434)Phase 3Viral Hepatitis
Est. primary completion 2026-12 · NCT07128550 · CT.gov ↗
What to watch
2029 (1)
March 2029 (1)
Tobevibart (VIR-3434)Phase 2Viral Hepatitis
Est. primary completion 2029-03 · NCT07142811 · CT.gov ↗
What to watch
2031 (1)
November 2031 (1)
Tobevibart (VIR-3434)Phase 2Hepatitis D, Chronic
Est. primary completion 2031-11 · NCT05461170 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 November 2026Topline resultTobevibart (VIR-3434)ECLIPSE 1 Phase 3 meets its primary endpoint
Vir Biotechnology · Source ↗

Financial reports

No financial reports recorded.